Division of Cardiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA.
Cardiol Rev. 2010 Jul-Aug;18(4):198-203. doi: 10.1097/CRD.0b013e3181d74582.
Organic nitrates have been used for over a century in cardiovascular therapy and are still widely used in the treatment of acute coronary syndromes, chronic angina pectoris, and congestive heart failure. Nitrates, together with sodium nitroprusside, generally referred to as nitrovasodilators, exert their biologic effects via the release of nitric oxide. They are also known as nitric oxide donors. The mechanism of action of these drugs is traditionally believed to lie in their arterial vasodilation and venodilation effects, resulting in an improvement of coronary artery blood supply and/or reduction of cardiac workload in the treatment of coronary artery disease and congestive heart failure. Recently it has been recognized that these drugs also have intrinsic antiplatelet and antithrombotic effects, demonstrated both in vitro and in vivo, which would add further rationale for the use of these drugs in atherothrombotic diseases. Research has shown that nitrovasodilators can nonselectively inhibit platelet aggregation induced by multiple stimuli. However, clinical trials have yielded conflicting results regarding clinical outcome, especially with long-term nitrate use. The potentially beneficial effects of nitrates could be negated by the development of tolerance and the generation of deleterious oxidative stress causing endothelial dysfunction during continuous nitrate administration. Much progress has been made in the development of new nitric oxide donors devoid of oxidant-generating properties. Novel combination therapies with nitrovasodilators plus antioxidants or agents with antioxidant properties have shown promise in reducing or reversing tolerance, potentiating antiplatelet effects, and improving clinical outcome. It is expected that clinical introduction of novel nitrovasodilator regimens will provide a new approach to the prevention and treatment of atherothrombotic diseases. Large-scale clinical trials will ultimately provide the evidence-based answers.
硝酸酯类药物在心血管治疗中已经使用了一个多世纪,目前仍广泛用于治疗急性冠状动脉综合征、慢性稳定型心绞痛和充血性心力衰竭。硝酸酯类药物与硝普钠(通常被称为硝基血管扩张剂)一起,通过释放一氧化氮发挥其生物学效应。它们也被称为一氧化氮供体。这些药物的作用机制传统上被认为在于其动脉扩张和静脉扩张作用,从而改善冠状动脉血液供应和/或减少冠心病和充血性心力衰竭患者的心脏负荷。最近,人们已经认识到这些药物还具有内在的抗血小板和抗血栓形成作用,这在体外和体内都得到了证实,这为这些药物在动脉粥样硬化血栓形成性疾病中的应用提供了进一步的理由。研究表明,硝基血管扩张剂可以非选择性地抑制多种刺激引起的血小板聚集。然而,临床试验在临床结果方面产生了相互矛盾的结果,特别是在长期使用硝酸盐时。在连续给予硝酸盐时,耐受性的发展和产生有害的氧化应激导致内皮功能障碍,可能会抵消硝酸盐的潜在有益作用。在开发无氧化剂生成特性的新型一氧化氮供体方面已经取得了很大进展。新型硝基血管扩张剂联合抗氧化剂或具有抗氧化特性的药物的联合治疗在减少或逆转耐受性、增强抗血小板作用和改善临床结果方面显示出了希望。预计新型硝基血管扩张剂方案的临床应用将为动脉粥样硬化血栓形成性疾病的预防和治疗提供一种新方法。大规模临床试验最终将提供基于证据的答案。